TW-37

For research use only.

Catalog No.S1121

42 publications

TW-37 Chemical Structure

CAS No. 877877-35-5

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 146 In stock
USD 160 In stock
USD 680 In stock
USD 1480 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's TW-37 has been cited by 42 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Targets
Mcl-1 [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
0.26 μM(Ki) 0.29 μM(Ki) 1.11 μM(Ki)
In vitro

TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human JAR cell NXXZVoxDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFHm[mlKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOkBvVQ>? MV\TRW5ITVJ?
human Ca9-22 cell MlfSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVPCT29xUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njh{IH7N NIXxRmJUSU6JRWK=
human CHL-1 cell NXLIdnlnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHf6VYZKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvQSCwTR?= M4HObHNCVkeHUh?=
human A549 cell NHXl[WxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mmm5TY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUSuNFkhdk1? NFnoUJlUSU6JRWK=
human RKO cell NEHoUVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHLaZYVKdmirYnn0bY9vKG:oIHj1cYFvKFKNTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlE4KG6P NInoVnpUSU6JRWK=
human GCIY cell M2WyVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGfxRppKdmirYnn0bY9vKG:oIHj1cYFvKEeFSWmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNE45OyCwTR?= M13wUnNCVkeHUh?=
human BHT-101 cell MnPVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkLETY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvQDNibl2= MXTTRW5ITVJ?
human Hs-578-T cell NFHRVHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVjMR4hXUW6qaXLpeIlwdiCxZjDoeY1idiCKcz21O|guXCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJ|LkW5JI5O NVG1NY1qW0GQR1XS
human SK-UT-1 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYrJcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE43QCCwTR?= NUjkOpdKW0GQR1XS
human NB7 cell NYL0ZlZjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3zSXWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkmuNlghdk1? NH3BO2FUSU6JRWK=
human YKG-1 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mnn3TY5pcWKrdHnvckBw\iCqdX3hckB[U0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK5Mlc3KG6P NHfic2hUSU6JRWK=
human HuH-7 cell NEjCSnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1fpTmlvcGmkaYTpc44hd2ZiaIXtZY4hUHWKLUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNk45OiCwTR?= MVXTRW5ITVJ?
human SAS cell NGHsWZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjRZpJ5UW6qaXLpeIlwdiCxZjDoeY1idiCVQWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zN{4yQCCwTR?= MmTLV2FPT0WU
human UACC-62 cell NX\3dXFGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4jjOWlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQz22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjN3IH7N NW\tRY5EW0GQR1XS
human AGS cell NFfZW2NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2HXSmlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{euOVMhdk1? MXfTRW5ITVJ?
human SK-MEL-30 cell NUjiSVdJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVXjR2VQUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Nz65O{BvVQ>? NVfIe2VnW0GQR1XS
human A427 cell MoqyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3P0R2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS0MlY6KG6P MUTTRW5ITVJ?
human DU-145 cell NFK4NGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MojUTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Nk4yOyCwTR?= MXLTRW5ITVJ?
human HCT-116 cell Mm[1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Nk43PiCwTR?= MlXpV2FPT0WU
human A673 cell NHn1UoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGPJRYNKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21N{45PSCwTR?= MkPsV2FPT0WU
human SF126 cell NFWwS3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX7N[o43UW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVU4NjB5IH7N NVy3N2d3W0GQR1XS
human SW872 cell NF7idmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV;4dY5sUW6qaXLpeIlwdiCxZjDoeY1idiCVV{i3NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVU5Njlibl2= MXrTRW5ITVJ?
human NCI-H1581 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M33vRWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVgyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjdwNkSgcm0> NWj4b|RoW0GQR1XS
human SK-MEL-5 cell NXywelF3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OlkvOjVibl2= M3viTXNCVkeHUh?=
human CP50-MEL-B cell NFPlWlhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1X5b2lvcGmkaYTpc44hd2ZiaIXtZY4hS1B3MD3NSWwuSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ7LkW5JI5O MULTRW5ITVJ?
human YH-13 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3vhfWlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23NE42QSCwTR?= NF7rfmZUSU6JRWK=
human LXF-289 cell NU[5VZdVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHrWfpFKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04Oi56NTDuUS=> MWnTRW5ITVJ?
human MC-IXC cell MnXrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIDmcnNKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVc2NjN|IH7N NWPyWWFpW0GQR1XS
human NB14 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIPwOJRKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Ok41PSCwTR?= NIXYbnZUSU6JRWK=
human HEC-1 cell M1rZRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkH2TY5pcWKrdHnvckBw\iCqdX3hckBJTUNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUixMlM4KG6P MnfiV2FPT0WU
human U-87-MG cell MlWzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHjj[mhKdmirYnn0bY9vKG:oIHj1cYFvKFVvOEetUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05Oi5{NDDuUS=> NWDXbnBVW0GQR1XS
human HOS cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnK0TY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16ND63NUBvVQ>? NWr6[XRRW0GQR1XS
human HUTU-80 cell NGDpbm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoLHTY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFcvODFibl2= NVXkR49FW0GQR1XS
human A375 cell NVLBcmlDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGTGO5NKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24PE45OyCwTR?= M3PFRnNCVkeHUh?=
human A204 cell NWrHdotHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mm\yTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OUeuPFQhdk1? MUHTRW5ITVJ?
human GB-1 cell MlvoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3zwV2lvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUm4MlY6KG6P M4KycXNCVkeHUh?=
human MDA-MB-231 cell M1fKXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYjFcpRZUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOjNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNFgxPyEQvF2= MXTTRW5ITVJ?
human SW982 cell M{\sZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NInKUo1KdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTB5IN88US=> MXnTRW5ITVJ?
human SW756 cell NYjIVm9XT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2rYXGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5NU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOjN4IN88US=> M3zVfXNCVkeHUh?=
human MG-63 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmnrTY5pcWKrdHnvckBw\iCqdX3hckBOTy14MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEzPDhizszN NWLtbYpxW0GQR1XS
human Daoy cell MlzoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NG\XS4VKdmirYnn0bY9vKG:oIHj1cYFvKESjb4mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE1ODd|IN88US=> NGDyXotUSU6JRWK=
human MDA-MB-453 cell M1uzfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVTSUFJmUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuPDV|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOVE5QCEQvF2= MkPzV2FPT0WU
human HT-144 cell Moi5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGfEfW9KdmirYnn0bY9vKG:oIHj1cYFvKEiWLUG0OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV{MEGg{txO MljGV2FPT0WU
human LoVo cell M2Xibmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1zkdWlvcGmkaYTpc44hd2ZiaIXtZY4hVG:YbzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVYxQTNizszN NWKxR5NwW0GQR1XS
human NY cell NFu0T|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV62[4pEUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVc4PjJizszN NFT3e5BUSU6JRWK=
human SW1783 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVnJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTd6MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlE{ODFizszN M3XkPXNCVkeHUh?=
human A2780 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIPPZ4xKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOTh2NjFOwG0> M2LV[3NCVkeHUh?=
human MDA-MB-361 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWH3NIFiUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlY1KM7:TR?= NWXxW5RUW0GQR1XS
human RPMI-2650 cell Mn;LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn;aTY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLUK2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|OEOxJO69VQ>? NEfQR|BUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]

Protocol

Kinase Assay:[1]
- Collapse

Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein :

For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].
Cell Research:[2]
- Collapse
  • Cell lines: HDMECs
  • Concentrations: 0 - 100 μM
  • Incubation Time: 96 hours
  • Method: The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
  • Dosages: ~40 mg/kg
  • Administration: Administered via i.v. or i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 115 mg/mL (200.45 mM)
Ethanol 4 mg/mL (6.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 573.7
Formula

C33H35NO6S

CAS No. 877877-35-5
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)C1=CC=CC=C1CC2=CC(=C(C(=C2O)O)O)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy TW-37 | TW-37 supplier | purchase TW-37 | TW-37 cost | TW-37 manufacturer | order TW-37 | TW-37 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID